[Applications of synthetic and semisynthetic polymers (Kollidon K25, Kollidon K90 and Hydroksyethylocellulose) as carriers of ketoprofen in solid oral prolonged release dosage forms. The impact of selected non-ionic surfactants (Tween 80 and Rofam 70) on the release kinetics].

BACKGROUND: Hydrophilic matrices used as oral forms of sustained release drugs are a suitable application medium for short-acting nonsteroidal anti-inflammatory drugs (NSAID) - ketoprofen. A properly selected hydrophilic matrix in oral preparations may significantly increase efficacy and application safety of ketoprofen. OBJECTIVES: The aim of the research was to analyze the usefulness of polymers (synthetic Kollidon K25 and K90, semi-synthetic hydroxyethylcellulose) and calcium hydrogen phosphate dihydrate (as an inorganic filler) in manufacturing solid oral matrix forms of ketoprofen and to study of the effect of non-ionic surfactants (Tween 80, Rofam 70) on release kinetics. MATERIAL AND METHODS: Ketoprofen, HEC, Kollidon K25, and K90, calcium hydrogen phosphate, magnesium stearate. Incorporation. Studies on the tablet mass. Direct tableting. Studies on the pharmacopoeial parameters and pharmaceutical availability. Approximation of the results. RESULTS: The results of the granulometric studies on tablet mass were in accordance with pharmacopoeial standards. The results of morphological and biopharmaceutical studies of the obtained matrices (tablets) were consistent with the pharmacopoeial standards for formulations with HEC, K25 and K90. The release results most closely related to row 0 kinetics were obtained for the matrix containing HEC and K25. Tween 80 added to 0.1N HCl accelerated the release of ketoprofen, while Rofam 70 decelerated it. Tween 80 and Rofam 70 added to the pH 7.4 buffer accelerated the release of ketoprofen. CONCLUSIONS: The presented model system of preformulation studies showed the usefulness of HEC and Kolidon K25 in the technology of hydrophilic matrices with ketoprofen. Surfactants added to the medium do not affect the release rate of ketoprofen.

[The Use of Synthetic Polymers (Superdisintegrants) in Technology Tablets Containing Ethanol Dry Extract from Asparagus officinalis]. / Zastosowanie syntetycznych polimerów (superdezintegrantów) w technologii tabletek zawierajacych etanolowy suchy wyciag z Asparagus officinalis.

BACKGROUND: Dry extracts are now frequently used in medicine as an alternative to synthetic drugs. In the case of tablet technology with dry plant extracts, the proper selection of disintegrants (superdisintegrants) is particularly important. Objectives. The aim of this study was to evaluate the usefulness of the polymers constituting superdisintegrants (Vivasol®, Vivastar®, Polyplasdone XL) in uncoated tablet formulation of alcoholic extracted from Asparagus officinalis. MATERIAL AND METHODS: Dry the ethanol extract of Asparagus officinalis, Vivasol®, Vivastar®, Vivapur®, Kollidon VA64, Polyplasdone XL, magnesium stearate. Direct compression. Paddle method was carried out to study pharmacopoeial parameters and pharmaceutical availability. The calculation of equivalency factors: similarity [f2] and the difference [f1]. Approximation results. RESULTS: Tablets brownish-green, with a smooth and uniform surface, without stains, chipping and damage. The determined average weight of the tablets compiled with the standards. The test friability and crushing strength revealed that the most mechanically strong tablets contained Vivasol, Vivastar, Polyplasdone XL. These tablets also have a longer disintegration and dissolution time compared with tablets containing only Vivasol. These differences are also confirmed by the calculated f2 and f1. CONCLUSIONS: The addition of a mixture of Polyplasdone XL and Vivastar to Vivasol significantly increases the mechanical strength of the tablets (crushing strength, resistance to crushing). The addition of a mixture of Polyplasdone XL and Vivastar to Vivasol paradoxically increases the disintegration time of tablets (11.1 min). Single superdisintegrant breaks up the tablet more effectively than a mixture of superdisintegrants.

Usefulness of Rosen's postulate for studying the relationship between the structure of cholic acid oxyethylation products and the process of solubilization of lipophilic therapeutic agents (BCS class II and IV) in aqueous solutions in equilibrium.

We verified the usefulness of "Rosen's postulate", i.e., the logarithm of reciprocal concentration of surfactant--log(1/cPi=20) by which the surface tension of a solution can be decreased by 20 mJ/m2 in relation to water (physiological value gamma25 = 48-52 mJ/m2) in the evaluation of the applicatory properties of cholic acid oxyethylation products. Moreover, the values of deltaG0m for solubilizers and their micellar adducts with diclofenac, naproxen, and loratadine constituted the basis for estimating the thermodynamic value of "Rebinder's effect", associated with change in the state of matter of therapeutic agent. We determined critical micellar concentration for the aqueous products of oxyethylation and for micellar adducts with diclofenac, naproxen, and loratadine, and used these values to calculate (thermodynamic potential of micelle formation).

Surface activity of novel surface active compounds, products of catalytic oxyethylation of cholic acid and their micellar adducts with selected lipophilic therapeutic agents.

The aim of this study was to determine the surface activity parameters of novel surface active compounds, products of catalytic oxyethylation of cholic acid, and their micellar adducts with selected lipophilic therapeutic agents (diclofenac, loratadine, naproxen and rutin). High solubility of lipophilic naproxen was observed in the environment of aqueous solutions of the cholic acid oxyethylation products as suggested by determined factual solubility and the value of micellar partition coefficient (K(w)(m)). Determined surface activity of surfactants described by various physicochemical characteristics (gamma(cmc)(25), cmc, deltaG(m)(o) and A(m)) suggested their compatibility with physiological values of the surface activity of plasma (48.0-52.0 mJ/m2) and lacrimal fluid (46.0-52.0 mJ/m2). Calculated values of HLB(1)(HNMR) and n(TE) of the micellar adduct in solid phase (solid dispersion) corresponded to an increase in its hydrophilicity, and, therefore, suggested possible mechanisms and site of diclofenac, loratadine, naproxen and rutin solubilization in the micellar structure (core or palisadic layer).

[The use of semi-synthetic polymers in the formulation of sucking and chewable tablets containing sage extract and zinc gluconate]. / Zastosowanie pólsyntetycznych polimerów w formulacji tabletek do ssania i zucia zawierajacych ekstrakt z szalwii i glukonian cynku.

BACKGROUND: Halitosis and gingivitis are most common pathologies (15-60% of population) which, if left untreated, lead to periodontal diseases and tooth loss. OBJECTIVES: The aim of this study was to develop, based on polymers of dry sage extract and zinc gluconate, tablets intended for sucking and chewing that can be applied in the treatment of halitosis and gingivitis. MATERIAL AND METHODS: Dried aqueous sage extract, zinc gluconate, Pharmagum M, Prosolv SMCC90 and SMCCHD90, Vivapur 102, sorbitol, mannitol, ludipress. Direct tableting. Testing pharmacopeial parameters and pharmaceutical availability (using basket and rotating disk methods) of tablets intended for sucking and chewing. Approximation of the obtained results. RESULTS: Grey and green color tablets were obtained with smooth and uniform surface, without stains, spalls or mechanical damage. The determined average mass (weight) of a tablet complied with the standard. The friability and crushing strength test revealed that tablets containing Prosolv SMCCHD90, Vivapur 102 and mannitol demonstrated the highest mechanical strength. Tablets containing these substances and intended for sucking had prolonged disintegration and release time. Tablets intended for chewing had a hardness at the level of 124 N.They demonstrated compressibility, low friability and prolonged release. The release profiles of tablets intended for sucking (v2) and those for chewing, obtained by basket and rotating disk methods, were similar. CONCLUSIONS: The addition of Prosolv SMCCHD90, Vivapur 102 and mannitol increased significantly the mechanical strength (higher hardness, lower friability), prolonged the disintegration time and slowed the release from the obtained tablets intended for sucking and chewing. The application of Prosolv SMCCHD90 in the formulation of tablets for chewing carries the risk for sorption of active components to the polymer structure. This process takes place in the early stage of the release. Rotating disk method used in pharmaceutical availability testing gives better results while analyzing the phenomenon than the standard basket method. The suggested and tested formulations of tablets intended for sucking and chewing may be used as an alternative to formulations containing dried titrated extracts from plants of antimicrobial activity (sage - Salvia officinalis) in combination with substances binding volatile sulfur compounds (zinc gluconate).

Solubilizing properties of new surface-active agents, products of catalytic oxyethylation of cholic acid.

Solubilizing properties of aqueous solutions of a series of surface-active agents, products of oxyethylation of cholic acid, were examined in the present study. The content of oxyethylated segments determined by means of the 1H NMR method enabled the verification of the molecular mass of surfactants along with the calculation of the structural hydrophilic-lipophilic balance (HLB), the solubility parameter delta1/2, and the required solubility level of balance HLB(R). Viscosimetric measurements enabled the calculation of the limiting viscosity number, the content-average molecular mass, the effective volume, the hydrodynamic radius of the surfactant micelle and their equilibrium adducts with rutin, diclofenac and loratadine (BCS Class II and III). By means of the spectrophotometric method (UV) the amount of the solubilized diclofenac, loratadine and rutin (rutoside) was determined in the equilibrium system (saturated solution) in the environment of aqueous solutions of cholic acid derivatives of n(TE) = 20-70. The obtained results serve as a basis for determining the solubilization mechanism of lipophilic therapeutic products and indirectly for estimating the influence of the above process on pharmaceutical as well as biological availability of a micellar adduct from model drug forms (Lindbladt lithogenolitic index).

[Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium]. / Wlasciwosci technologiczne i farmakoterapeutyczne wybranych produktów leczniczych o modyfikowanym uwalnianiu soli sodowej diklofenaku.

AIM OF THE STUDY: Diclofenac and its sodium salt is one of the best-known and popular therapeutic agents from the group of NSAIDs used in medicine in many various pharmaceutical forms. Therapeutic products containing diclofenac sodium salt in doses of 100 mg and 75 mg with a qualitatively and quantitatively diversified share of excipients and a variable dosage form of the drug (solid capsules, tablets with modified release) were subjected to technological and pharmaceutical analysis. The effect of solid formulation components of polymer character making the core and the coating of the pharmaceutical form of therapeutic products on the disintegration time and pharmaceutical availability in pharmacopoeial receptor fluids was estimated. MATERIALS AND METHODS: Market therapeutic products with diclofenac sodium in doses of 75 mg and 100 mg, technological analysis of the drug dosage form was conducted, disintegration time of solid oral dosage forms of the drug with diclofenac sodium salt was examined and research on pharmaceutical availability of diclofenac sodium salt from tested therapeutic products was conducted using the acid phase and the buffer phase according to the FP standards for delayed release enteral dosage forms. The experimental data was supplemented with the statistical analysis. RESULTS: There are three formulations in the form of solid capsules and one formulation in the form of a coated tablet. All therapeutic products bear features of a dosage form of modified release of diclofenac sodium salt, frequently of a delayed release formula in the duodenum or the small intestine with regard to the limitation of typical undesirable effects after taking NSAIDs. Considerable diversity between solid capsules and the tablet with modified release during disintegration or hydration and swelling has been observed. In the environment of a receptor fluid--purified water (pH = 7) the capsule Dicloberl retard disintegrates at the fastest rate in 5,49 minutes, and then in the order: DicloDuo 75 mg--8,13 minutes and Olfen 100 SR--11,27 minutes. The hydration degree of gelatin walls of capsules depends on the pH of the receptor fluid. The availability of diclofenac sodium salt in given receptor fluids confirms the fact of significant connection of clinical effectiveness of the tested pharmaceutical forms with the activity of hydrogen ions (pH) of the environment in which there are therapeutic products, and excipients used for making the pharmaceutical phase. CONCLUSIONS: Tested therapeutic products with diclofenac sodium salt are differentiated by the type of a dosage form. Dicloberl retard contains the minimally indispensable number of simple, commonly used excipients. The research on the disintegration time may only be related to the products Dicloberl retard, Olfen 100 SR and DicloDuo 75 mg treating it as the time of deformation and disintegration of a capsule. In all three types of receptor fluids, the capsule Dicloberl retard has the fastest disintegration rate. The "acid phase" demonstrated stability of the products with a slight dissolution of diclofenac sodium salt on the level 1,3-4,18% of the Q release coefficient. In the environment of artificial intestinal juice, Dicloberl retard is more effective releasing larger amounts of diclofenac sodium salt during 4 hours of exposition (differences from 10% to 14% of the Q release coefficient).

[Polymers as excipients used in the technology of coated tablets containing ibandronic acid derivatives (bisphosphonates)]. / Polimery jako substancje pomocnicze stosowane w technologii tabletek powlekanych zawierajacych pochodne kwasu ibandronowego (bisfosfoniany).

Bisphosphonates are used in the treatment of osteoporosis, predominantly most often postmenopausal and glucocorticoid-induced forms. The most commonly known bisphosphonates are: derivatives of alendronic, clodronic, ibandronic, risedronic acid. Bisphosphonates have low bioavailability (1-10%) and low absorption (for more recent bisphosphonates it does not exceed 1%) after oral application (class III of BCS). The discussed group of derivatives is also a technological challenge, particularly in a situation of so difficult biopharmaceutical conditions. The above encourages compliance with the discipline of taking solid oral pharmaceutical forms (tablets), which have to be taken strictly on an empty stomach (30-60 minutes before a meal) and washed down with a glass of boiled water. The technology of oral drug forms with bisphosphonates has to minimize practically to zero the problems of potential adsorption of an active substance on excipients of a character of macromolecular polymers being part of a tablet core and a coating, at the same time providing full pharmaceutical availability.

[The influence of macromolecular excipients on the process of mass transfer at the boundary phase from a model anti-dandruff preparation into the external compartment under in vitro conditions]. / Wplyw wielkoczasteczkowych substancji pomocniczych na proces wymiany masy na granicy faz z modelowego preparatu przeciwlupiezowego do kompartmentu zewnetrznego w warunkach in vitro.

AIM OF THE STUDY: The aim of the research was the application assessment of a model preparation--anti-dandruff emulsion. The experiments was conducted under in vitro conditions using of a model system of human skin, which are cellulose dialysis membranes with a standardized pore size. The behaviour of the preparation on the dialysis membrane was analyzed, and the degree of film formation performing the function of a protective barrier was evaluated after gentle rinsing with tepid water without cleaning agents. It was checked whether the product layer remaining on the membrane product layer does not block diffusion and penetration processes. Additionally, an attempt to assess the character of the layer with the use of a hydrophilic marker was made. MATERIALS AND METHODS: Model anti-dandruff emulsion, Servapor Dialysis Tubing 100 dialysis membranes with a wall thickness d = 0.1 mm and a declared pore diameter phi = 25 A degrees, sodium chloride, purified water--assessment of the residue level of the analyzed preparation on the dialysis membrane. Examination on the marker diffusion through the dialysis membrane covered with the model anti-dandruff preparation, Approximation of the obtained results. RESULTS: The first phase of the experiment was the preparation of dialysis membranes for the adsorption process of a model anti-dandruff preparation, then its adsorption, rinsing with tepid water and the measurement of residue level of the product on the membrane control. It has been observed that the mass of the membrane on which the preparation was applied increased in relation to the membrane from a control sample. The mass increase of the membrane in a research sample is accompanied with the increase of its thickness caused by the adsorbed amount of the product and water on the membrane. The diffusion through the membrane in a control sample turned out to be slightly slower what may indicate the character of the membrane residue of the model anti-dandruff preparation. CONCLUSIONS; The technology of model anti-dandruff emulsion enables the formation of a layer forming a specific protective barrier on the surface of the dialysis membrane. The presence of the layer of model anti-dandruff emulsion on the membrane is confirmed by mean values of mass and thickness increase of the dialysis membrane. The hydrophobic diffusion layer is of a variable character. The properly applied emulsion under "in vivo" conditions might fill voids of the corneal layer of epidermis creating a structure of a film character performing the function of a protective barrier. On the basis of the in vitro assessment, the therapeutic effectiveness under in vivo conditions may be concluded.

[The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release]. / Zastosowanie hydrofilowych syntetycznych i naturalnych polimerów w formulacjach tabletek z chlorowodorkiem metforminy o róznym profilu uwalniania.

AIM OF STUDY: Metformin hydrochloride after buformin and phenformin belongs to the group of biguanid derivatives used as oral anti-diabetic drugs. The object of the study is the technological analysis and the potential effect of biodegradable macromolecular polymers on the technological and therapeutic parameters of oral anti-diabetic medicinal products with metformin hydrochloride: Siofor, Formetic, Glucophage, Metformax in doses of 500mg and 1000mg and Glucophage XR in a dose of 500 mg of modified release. MATERIALS AND METHODS: Market therapeutic products containing 500 and 1000 mg of metformin hydrochloride in a normal formulation and 500 mg of metformin hydrochloride in a formulation of modified release were analyzed. Following research methods were used: technological analysis of tablets, study of disintegration time of tablets, evaluation of pharmaceutical availability of metformin hydrochloride from tested therapeutic products, mathematical and kinetic analysis of release profiles of metformin hydrochloride, statistical analysis of mean differences of release coefficients. RESULTS: The percentage of excipients in the XR formulation is higher and constitutes 50.5% of a tablet mass. However, in standard formulations the percentage is lower, between 5.5% and 12.76%. On the basis of the results of disintegration time studies, the analysed therapeutic products can be divided into two groups, regardless the dose. The first one are preparations with faster (not fast!) disintegration: Glucophage i Metformax. The second group are preparations with slower disintegration, more balanced in the aspect of a high dose of the biologically active substance: Formetic and Siofor. Products with a lower content of excipients (Metformax, Glucophage) disintegrate in a faster way. The disintegration rate of the products with a higher content of excipients (Formetic, Siofor) is slower. The appearance of metformin hydrochloride concentration in the gastrointestinal contents, balanced in time, caused by a slower disintegration-dissolving of a tablet, is conducive to the reduction of gastrointestinal side effects and better tolerance of the therapeutic product by a patient. The study on pharmaceutical availability indicated relevant kinetic differences between tested therapeutic products. They are particularly visible between standard formulations and the one with prolonged release (Glucophage XR500). Its release profile bears features of kinetics similar to zero-order reactions. CONCLUSIONS: Tested therapeutic products contain a large amount of the biologically active substance in relation to the content of excipients. A higher content of excipients in a single tablet mass distinguishes Siofor in comparison with Glucophage i Metformax. The excipients used in the formulations of tested preparations are comparable. A higher percentage of binding agents (HPMC, PVP) is observed, but there is a lack of typical disintegrants which results in a longer disintegration time up to 15 minutes. Siofor disintegrates at the same time as Formetic, but longer than Glucophage i Metformax. Considering the large content of the active substance and pharmacological properties of metformin hydrochloride, such a disintegration might have beneficial consequences, because the amount of the free active substance in the gastrointestinal tract will increase over the longer time period what will reduce the level of gastrointestinal side effects. The release profiles of metformin hydrochloride from tested therapeutic products are comparable. The Glucophage XR 500 formulation with the release kinetics of metformin hydrochloride similar to the zero-order kinetics is completely different from the others. The above is confirmed by the mathematical analysis of release profiles of metformin hydrochloride from tested preparations where equations of lines describing the release profile are characterized by similar values of correlation coefficients.

[Eurand Minitabs--the innovative application formula of a pancreatic enzyme complex (Pangrol 10,000, 25,000)]. / Eurand Minitabs--innowacyjna formula aplikacji kompleksu enzymatycznego pankreatyny (Pangrol 10,000, 25,000).

Modern technology of solid oral drug forms, through the application of macromolecular polymers, generates a number of new formulation solutions. New technologies provide optimal parameters for the release of biologically active substances, increasing by these means pharmacotherapeutic effectiveness of a medicinal product. Basic properties of the innovative Eurand Minitabs technology, making possible the tableting of technologically and applicatively labile substances such as a pancreatic enzyme complex were dicussed. The application of encapsulated minitablets coated with a methacrylic acid copolymer guarantees an optimal range of lipase pharmacological activity.

Chromatographic analysis of new nonionic surfactants of oxyethylation products in the presence of calcium catalyst of rapeseed oil fatty acid methyl esters (RME).

Various methods of chromatographic analysis (GPC, HPLC, TLC) were used to estimate qualitatively and quantitatively the product of oxyethylation of rapeseed oil acid methyl esters (RME). The investigation enabled to evaluate PEG content in the product. The method of eliminating insignificant quantity of PEG found in oxyethylation products of n(TE) < or = 20 was presented. The data of thin-layer chromatography obtained in the course of research constitute a point of departure for calculating n(TE) content and HLB level.

[Ibuprofen release preferences of medicinal products, the market share of excipients vement of a polymer]. / Preferencje uwalniania ibuprofenu z rynkowych produktów leczniczych determinowanych udzialem substancji pomocniczych o charakterze polimerów.

On pharmaceutical market, beside technological variability of the forms of a drug with ibuprofen, there also occurs variability of chemical and crystallographic forms of ibuprofen itself. The above allows to use ibuprofen not only in the form of pure acid, but also forms of ibuprofen sodium salts or hydrophilic solubilized complexes of very good solubility in water. The above influences changeability of technological parameters measured with the use of methods of quality control being the pharmacopeal standard. On the basis of information collected in pharmacies, it can be also considered that pharmacological effect of identical forms of drugs with ibuprofen in the same dose is differently perceived by patients expecting comfort of the process of treatment, the result of which is to be effective. The above arguments induce undertaking studies on the estimation of differences occurring between particular market versions of the forms of a drug with ibuprofen.

[Microcrystalline cellulose and their flow -- morphological properties modifications as an effective excpients in tablet formulation technology containing lattice established API and also dry plant extract]. / Celuloza mikrokrystaliczna i jej granulometryczno -- morfologiczne modyfikacje, jako efektywne substancje pomocnicze w technologii tabletkowania srodków leczniczych o ustalonej strukturze krystalograficznej, a takze suchych mianowanych ekstraktów roslinnych.

The production technology of powder cellulose (Arbocel) and microcrystaline cellulose (Vivapur) and their application in the composition of direct compression tablet mass was provided. The function of silicified microcrystaline cellulose type Prosolv in the direct compression process of dry plant extract was discussed. An analysis of the chemical structure of cellulose fiber (Vitacel) enabled determining its properties and applications in the manufacture of diet supplement, pharmaceutical and food products.

[Starch and its derivatives as excipients in oral and parenteral drug form technology]. / Skrobia i jej pochodne jako substancje pomocnicze w technologii doustnej i parenteralnej postaci produktu farmaceutycznego.

The morphological and structural properties of basic types of starch used as excipients in solid drug form technology with reference to its bioadhesive properties with fully polymer biodegradation. The production technology and application of: carboxymethyl starch (CMS), pregelled starch, hydroxyethyl starch (HES), hydroxypropyl starch (HPS) and the share of modified starch in technology of selected food products is provided. The authors focus on hydroxyethyl starch, which is used not only as blood and plasma substitution but also as drug camouflage agent in sports competition. In papers were presented based on literature data actually used types of starch and their chemical modifications products in drug forms and food technology.

Solubilizing properties of new surface-active agents, products of selective oxyethylation of cholic acid. Part I.

Research was conducted into the properties and identity of the products of oxyethylation of cholic acid, which were obtained with the use of a selective catalyst (K4). The 1HNMR method was employed to assess the content of oxyethylated segments and the analytic level of hydrophilic-lipophilic balance (HLB). Surface activity of the products of oxyethylation in water and 0.1 M HCL was examined and cmc and gamma(25)cmc were determined. These were employed to calculate the thermodynamic potential for micelle formation deltaG(o)m and the surface occupied by the lipophilic structure of the surfactant at the phase boundary. Basic viscosity and hydrodynamic values were determined for the solubilizers and their micellar adducts with diclofenac, ketoprofen, fenofibrate, gemfibrozil and nifedipine. In addition, the amount of solubilized therapeutic agents c/s/ was examined by means of the spectroscopic method and the H/L balance in a solid state. The results obtained in the course of research served as a basis for determining the solubilization mechanism and the stability of the micellar adduct for the purpose of application.

Solubilizing and lithogenolitic properties of water solutions of non-ionic surfactants of cholesterol oxyethylenation products.

Research was conducted into the properties and identity of the products oxyethylenation of cholesterol, which were obtained with the use of a selective catalyst (K-4) and standard alkaline catalyst (Na/NaOH). The 1HNMR method was employed to assess the content of oxyethylated segments and the analytic level of hydrophilic--lipophilic balance (HLB). Basic viscosity and hydrodynamic values were determined for the solubilizers and their micellar adduct with ibuprofen, ketoprofen, naproxen and cholesterol. In addition, the amount of solubilized therapeutic agents and cholesterol as well as the micellar partition coefficient--K(m)w. was estimated. The results obtained in the course of research served as a basis for determining the solubilization mechanism and the stability of the micellar adduct for the purpose of application.